# 1 Gene-Specific Common Deletion Regions and Detection of Gene Copy Number

### 2 Deletion

- 3 Running title: Gene-specific common deletion regions
- 4 Yuan Tian, Ph.D. <sup>1#</sup>, Rui Xing, Ph.D. <sup>2#</sup>, Jing Zhou <sup>1#</sup>, Juanli Qiao, Ph.D. <sup>1</sup>, Zhaojun Liu, Ph.D. <sup>1</sup>, Liankun Gu<sup>1</sup>,
- 5 Baozhen Zhang, Ph.D. <sup>1</sup>, Youyong Lu, M.D. <sup>2</sup>, Dajun Deng, M.D. <sup>1</sup>\*
- <sup>1</sup> Key Laboratory of Carcinogenesis and Translational Research (MOE/Beijing), Division of Etiology, Peking
- 7 University Cancer Hospital and Institute, Beijing, 100142, China;
- 8 <sup>2</sup> Key Laboratory of Carcinogenesis and Translational Research (MOE/Beijing), Division of Tumor Biology,
- 9 Peking University Cancer Hospital and Institute, Beijing, 100142, China
- 10 # Equal first authors
- 11 \*Corresponding author: Dajun Deng, Key Laboratory of Carcinogenesis and Translational Research
- 12 (MOE/Beijing), Division of Etiology, Peking University Cancer Hospital and Institute, Fu-Cheng-Lu #52,
- Haidian District, Beijing, 100142, China, Phone: +8610-88196752 (E-mail: dengdajun@bjmu.edu.cn)
- 14 Word count: 3945

**Abstract** 

1

17

2 A feasible method to detect somatic copy number deletion (SCND) of tumor suppressor genes is still absent 3 up to date. To overcome the obstacle of SCND detection, we analyzed genomic coordinates of gene deletion 4 fragments using the Catalogue Of Somatic Mutation In Cancer (COSMIC) datasets. Interstitial 5 base-resolution deletion/fusion coordinates for CDKN2A were extracted from published articles and our 6 whole genome sequencing (WGS) datasets. The results showed that estimated common deletion regions 7 (CDRs) were observed in many tumor suppressor genes, such as ATM, CDKN2A, FAT1, miR31HG, PTEN, and 8 RB1 in the SNP array-based COSMIC datasets. A 5.1-kb base-resolution CDR could be identified in >90% 9 cancer samples by sequencing. Using the true CDKN2A CDR as a PCR target, a multiplex quantitative PCR 10 assay P16-Light was programmed to detect CDKN2A gene copy number with a lower detection limit of 20%. 11 P16-Light was further confirmed with WGS as the gold standard among cancer tissue samples from 139 12 patients. In conclusion, CDRs are common in many tumor suppressor genes. The 5.1-kb CDKN2A CDR was 13 found in >90% cancers containing CDKN2A deletion. The CDKN2A CDR was used a potential target for 14 developing the P16-Light assay to detect CDKN2A SCND and amplification for routine clinical practices. 15 Key words: somatic copy number variation (SCNV); common deleted region (CDR); tumor suppressor gene; 16 CDKN2A; whole genome sequencing (WGS)

## Introduction

1

28

29

30

2 Somatic copy number variations (SCNVs) of tumor related genes are landmarks of human cancers (1,2). Somatic copy number deletion (SCND) and amplification are two kinds of well-known SCNVs. However, 3 4 current gene copy number detection methods, including microsattelite instability (MSI), loss/gain of 5 heterozygosity (LOH/GOH), fluorescence-in-situ hybridization (FISH), whole genome sequencing (WGS) or 6 whole exome sequencing (WES), are not sensitive enough or too costly for routine clinical use. While the 7 amplification of oncogenes (such as EGFR, c-ERBB2, c-MYC, and c-MET) are increasingly driving 8 decision-making for precise cancer treatments, clinical applications of SCND of tumor suppressor genes, including CDKN2A, are still rare owing to the lack of a feasible detection assay. 9 10 The frequency of CDKN2A SCND detected by single nucleotide polymorphism (SNP) microarray, WGS or WES was found to range from 30% to 60% in bladder cancer, melanoma, head and neck cancer, pleural 11 12 mesothelioma, glioblastoma, and esophageal squamous cell cancer (ESCC) with an average frequency of 13% in pan-cancer datasets in The Cancer Genome Atlas (TCGA) (Figure S1A) (2-6). CDKN2A deep-deletion is 13 associated with downregulation of the CDKN2A gene expression, while CDKN2A amplification is associated 14 15 with upregulation of the CDKN2A gene expression in Pan-TCGA cancers (Figure S1B). It is well known that 16 genetic CDKN2A inactivation contributes to malignant transformation, cancer metastasis, and therapy sensitivity of cancers to drugs, including CDK4/6 inhibitors and their combination with PD-1 blockades (7-11). 17 Therefore, a convenient and sensitive assay to detect CDKN2A SCND is eagerly awaited. 18 19 In the present study, we characterized patterns of estimated genomic coordinates for SCNDs in a set of 20 tumor suppressor genes using public Catalogue Of Somatic Mutations In Cancer (COSMIC) SCNV datasets 21 and found common deletion regions (CDRs) in many frequently deleted genes. Then, we further defined a 22 5.1-kb base-resolution CDR within the CDKN2A gene using sequencing data for the first time. A sensitive 23 P16-Light assay targeted to the CDKN2A CDR was established for clinical practices. Methods & Material 24 **COSMIC and TCGA SCNV datasets** 25 26 SNP6 array-based Estimated genomic coordinates of interstitial copy number deletion/fusion of the CDKN2A 27 gene in cancer cell lines (n=273) with homozygous CDKN2A deletion and estimated genomic coordinates of

project (Data file 1-11) (12).

deep-deleted fragments of CDKN2A, PTEN, RB1, and other frequently deleted genes in cancer tissues were

downloaded from were downloaded from the Copy Number Analysis (CONA) datasets in the COSMIC

#### Patients, tissues, and DNA preparation

1

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

2 Frozen fresh GC and paired surgical margin (SM) tissue samples were collected from 156 patients in the 3 WGS study (13). These samples were frozen in liquid nitrogen about 30 min after surgical dissection and 4 then stored in a -80° C refreezor for 2-5 yrs. Clinicopathologic information were also obtained. The 2010 5 UICC tumor-node-metastasis (TNM) system was used to classify these GCs (14). Genomic DNA was extracted 6 from these samples with a phenol/chloroform method coupled with RNase treatment. Concentrations of 7 these DNA samples were determined with NanoVue Plus (Biochrom LTD, Cambridge, UK). DNA samples with 8 OD<sub>260nm</sub>/OD<sub>280nm</sub> ratios ranging from 1.7 to 1.9 were used for detection of gene copy number as described 9 below.

#### Optimized quantitative multiplex PCR assay (P16-Light) to detect CDKN2A copy number

A number of multiplex primer and probe combinations were designed based on the best multiplex primer probe scores for conservative sequences within the CDR in the CDKN2A (HGNC: 1787) and GAPDH (HGNC: 4141) gene sequences by Bacon Designer 8 software. Multiplex PCR assays were established according to the Applied Biosystems (ABI) TaqMan universal PCR master mix manual. The performance of these assays for the detection of CDKN2A copy numbers was compared with each other. Finally, a multiplex primer and probe combination targeted to CDKN2A intron-2 was selected (Table 1) and their components' concentrations were optimized. Each multiplex PCR assay was carried out in a total volume 20 µL that included 5-10 ng of input DNA, 10  $\mu$ M of forward and reverse primers and probe for CDKN2A intron-2, 10 μM forward and reverse primers and probe for GAPDH, and 10 μL of 2 x TaqMan Universal Master Mix II with uracil-N-glycosylase (Kit-4440038, ABI, Lithuania). The PCRs were performed in triplicate in a MicroAmp Fast Optical 96-Well Reaction Plate with a barcode (0.1 mL; ABI, China) with an ABI 7500 Fast Real-Time PCR System. The specific conditions of the PCR were as follows: initial incubation for 10 min at 95°C, followed by 40 cycles of 95°C for 20 sec and 58°C for 60 sec. When Ct value for GAPDH input for a sample was 34 or fewer cycles, this sample was considered as CDKN2A SCNV informative. The specificity of PCR reaction was monitored through running gel. Distilled water was used as no template control for each experiment.

### Definitions of CDKN2A CDR deletion-positive and amplification-positive

We used the genomic DNA from A549 cells containing no *CDKN2A* allele to dilute genomic DNA from RKO cells containing 2 wild-type *CDKN2A* alleles, and then we set the standard curve according to the relative copy number of the *CDKN2A* gene at different dilution concentrations. The  $\Delta$ Ct value and relative copy

1 number for the CDKN2A gene were calculated using the GAPDH gene as the internal reference. When the 2 CDKN2A copy number in the A549-diluted template was consistently lower than that in the RKO control 3 template, and the difference was statistically significant (t-test, p<0.05), it was judged that the lowest 4 dilution concentration was the detection limit of CDKN2A deletion (the difference in CDKN2A copy number 5 between the 100% RKO template and 80% RKO template spiked with 20% A549 DNA). When the CDKN2A 6 relative copy number in a tissue sample was significantly lower or higher than that of the paired SM sample, 7 the sample was defined as somatic CDKN2A CDR deletion-positive or amplification-positive, respectively. 8 For each experiment, the 100% A549, 100% RKO, and 20% A549 + 80% RKO DNA mix controls were 9 analyzed. Quantitative detection of CDKN2A/P14<sup>ARF</sup> exon-1β copy number by PCR assay (P14-qPCR) 10 11 The copy number of CDKN2A exon-1 $\beta$  was detected uising the primer and probe set (Table 1) as previously 12 reported (15). When the relative copy number of CDKN2A exon-1 $\beta$  in a tissue sample was significantly lower or higher than that of the paired SM sample, the sample was defined as somatic CDKN2A/P14AFF 13 14 deletion-positive or amplification-positive, respectively. 15 Call for CDKN2A interstitial deletion/fusion and calculate purity of cancer cells in the GC WGS datasets 16 We used Meerkat 23 to predict somatic SVs and their breakpoints in WGS datasets (accession numbers, 17 EGAD00001004811 with 36× of sequencing depth) for gastric adenocarcinoma samples from 168 patients 18 using the suggested parameters (13). This method used soft-clipped and split reads to identify candidate 19 breakpoints, and precise breakpoints were refined by local alignments. CDKN2A deletion information of 157 20 GC samples was obtained from WGS datasets. We also estimated copy number profiling over 10-kb 21 windows with Patchwork 28 and calculated the ratio of standardized average depth between normal tissue 22 and tumor tissue (log2R ratio). The purity and ploidy of each tumor were calculated using ABSOLUTE 23 software (16). 24 Cell lines and cultures The CDKN2A allele homozygously deleted cell line A549 (kindly provided by Dr. Zhiqian Zhang of Peking 25 26 University Cancer Hospital and Institute) were grown in RPMI-1640 medium, and the RKO cell line 27 containing two wild type CDKN2A alleles was purchased from American Type Culture Collection and grown 28 in DMEM media. The medium was supplemented with 10% (v/v) fetal bovine serum (FBS). These cell lines 29 were tested and authenticated by Beijing JianLian Genes Technology Co., Ltd. before they were used in this 30 study. A Goldeneye<sup>TM</sup> 20A STR Identifiler PCR Amplification kit was used to analyze the STR patterns.

#### Statistical analysis

1

6

7

9

10

11

12

13

14

15

16

17

18

20

22

23

24

25

26

27

28

29

- 2 Chi-square or Fisher's exact tests were used to compare the proportion of CDKN2A SCND or amplification
- 3 between different groups of tissue samples. Student t-test was used to compare the proportion of the
- 4 CDKN2A gene copy number between genomic DNA samples. All statistical tests were two-sided, and p value
- 5 less than 0.05 was considered to be statistically significant.

### Results

#### Prevalence of estimated CDRs within various tumor suppressor genes

8 It has been previously reported that homozygous deletion of approximately 170 kilobase pairs (kb),

including the CDKN2A locus, can be detected in human cancers by MSI analyses (17). SCND inactivates the

CDKN2A gene in 273 human cancer cell lines according to the COSMIC dataset (Data file 1). We found that

an 8-kb estimated CDKN2A CDR could be detected among these cell lines through ording "start" coordinates

of these breaking points (Figure S1). To investigate the prevalence of CDRs within tumor suppressor genes in

human cancer tissues with a high deletion frequency (1,2), we further downloaded the estimated genomic

coordinates for deletion fragments that overlap with these genes, respectively. We found that CDRs could

be detected not only within the CDKN2A gene (Figure 1A; about 17-kb), but also within ATM (middle to

downstream), FAT1 (promoter to middle), miR31HG (promoter to exon-1), PTEN (promoter to exon-1), and

RB1 genes (promoter to intron-2) (Figure 2; about 158-kb, 23-kb, 33-kb, 5-kb, and 2442-kb, respectively)

(Data file 2-7). No CDR could be observed within CCSER1, FHIT, LRP1B, and WWOX genes according to the

19 SNP-array data (Data file 8-11).

#### Characterization of a true CDKN2A CDR at the base-resolution in human cancers

21 It was reported that the error in CDKN2A breakpoint estimation based on SNP-array data is roughly 10-kb

(18). To characterize true genomic coordinates of CDKN2A deletion fragments in cancers, we extracted

base-resolution sequence information of interstitial CDKN2A deletions from available published articles and

our sequencing data (Data file 12) (19-28). We found a 5.1-kb CDR (chr9: 21,970,277 - 21,975,386, hg19)

that spanned from the P16<sup>INK4a</sup> promoter to intron-2 in 83 (90%) of 92 reported cancer cell lines or tissue

samples containing interstitial CDKN2A deletions (Figure 1B, blue lines). This CDR sequence is the same as

the CDKN2A deletion fragment in the HCC193 lung cancer cell line (25). The CDR coordinates were also

confirmed in our WGS datasets (average sequencing depth, 36×) of 18 (100%) of 18 GCs (13), in which

interstitial CDKN2A deletions/fusions were identified (Figure 1B, purple lines; Data file 12).

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

It is well known that germline CDKN2A inactivation can lead to a high predisposition for melanoma and pancreatic cancer (29-31). Interestingly, we found that 14 (93.3%) of 15 CDKN2A allelic variants in the Online Mendelian Inheritance in Man (OMIM) database are located within the CDR sequence, especially in CDKN2A exon-2 (Figure S3) (32,33). In addition, both P16<sup>INK4a</sup> and P14<sup>ARF</sup> mRNAs are transcribed from the human CDKN2A gene at chromosome 9p21 but with different transcription start sites; they share the same exon-2 but have different translation reading frames. Because the CDKN2A exon-2 located within the true CDR is the essential exon for coding P16<sup>INK4a</sup> and P14<sup>ARF</sup> proteins, the above findings indicate that P16<sup>INK4a</sup> and P14<sup>ARF</sup> are co-inactivated in 87% (96/110) of human cancer cell lines and tissues containing CDKN2A CDR deletion (Figure 1B). Establishment of a convenient PCR assay (P16-Light) to detect somatic CDKN2A CDR deletion The current clinical method FISH for detecting SCND is composed of a set of biotin-labeled probes that should cover at least 50-kb DNA sequence. Thus, FISH is not a suitable method for detecting the copy number deletion of the 5.1-kb CDKN2A CDR. To provide a convenient way for routine clinical use, we designed and experimentally evaluated a set of multiplex quantitative PCR assays and finally optimized the CDKN2A CDR-specific quantitative multiplex PCR assay called P16-Light for detecting the copy number of a 129-bp amplicon within the CDKN2A intron-2 (Figure 3A), which covers 86% (94/110) of known CDKN2A deletion fragments (Figure 1B, violet line). The copy number of the GAPDH gene was used as the internal reference. Genomic DNA from human A549 cells (with homozygous deletion of CDKN2A alleles) and RKO cells (with 2 wild-type CDKN2A alleles) were used as CDKN2A CDR deletion-positive and deletion-negative controls, respectively. The amplification efficiency of two amplicons in GAPDH and CDKN2A were very similar (Figure 3B). No template inhibition was abserved when the amount of template DNA ranged from 10 to 0.63 ng (Figure 3C). The proportions of CDKN2A CDR copy number were linearly correlated with the ratios (0 - 100%) of RKO cell DNA and A549 cell DNA in the input mixtures (10 ng/reaction) when the A549 DNA was spiked in at different proportions for the P16-Light analyses (Figure 3D). Furthermore, there was a high reproducibility when DNA with homozygous deletion of CDKN2A was present in ≥20% of the cells verified in ten experimental repeats performed on different days (Figure 3E). Thus, when the proportion of CDKN2A copy number was significantly decreased (or increased) in a sample relative to the paired normal control (t-test, p<0.05) in the P16-Light analyses, the sample would be defined as CDKN2A SCND-positive (or amplification-positive).

#### Comparison of P16-Light with WGS datasets

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

As we described above, information on interstitial copy number deletion/fusion of the CDKN2A gene was extracted from WGS datasets for 156 of 168 GC patients enrolled in a GC genome study (13) and a total of 18 CDKN2A deletion/fusion coordinates at the base-resolution were detected in 17 (10.8%) GCs (Data file 12 and 13). To compare the performance of P16-Light with WGS, we analyzed the status of SCNVs, including SCND and amplification, of the CDKN2A gene in 156 of these GCs with enough amounts of genomic DNA samples with P16-Light using the paired surgical margin tissue (SM) as the diploid reference (Data file 13). CDKN2A SCND and amplification were detected in 40 (25.6%) and 34 (21.8%) of these GCs, respectively. The P16-Light analysis was confirmed by the WGS results: the frequency of CDKN2A SCND (or amplification) by P16-Light was significantly higher (or lower) in 17 GCs containing interstitial CDKN2A deletion/fusion than those 139 GCs without (chi-square test, p<0.028; Figure 4A). These results also indicate that there is a significantly higher sensitivity for detecting CDKN2A SCND by the quantitative P16-Light assay than the hemi-quantitative WGS. Moreover, it is well known that the propertion of cancer cells in tissue samples (ie. sample purity) may affect the detecton values of various genome data. To study whether cancer cell proportion disturbs detection of CDKN2A SCNVs, we calculated cancer cell propertion in above GC samples using WGS data (Data file 13). We found that the difference in sample purity between GC subgroups with the different status of CDKN2A SCNVs was not statistically significant (t-test, p=0.075; Figure 4B), although the propertion

was slightly higher in the GCs with CDKN2A SCND than thoses without. No correlation was observed

between the proportion of cancer cells and relative copy number of the CDKN2A gene among these GCs

(Figure 4C).

## Comparison of P16-Light with P14-qPCR assay

The P14-qPCR assay was previously established for detecting the copy number of  $CDKN2A/P14^{ARF}$  exon-1 $\beta$  (15). Two amplicons in the P16-Light and P14-qPCR assays cover 98% (108/110) of known CDKN2A deletion fragments (Figure 1B, violet and green lines). Therefore, we further compared the performance of P16-Light, P14-qPCR, and their combination using GCs and paired SM samples from patients who were recently included in the cross-sectional cohort in our association study (34). GC samples (n=139) with enough amount of genomic DNA were used in P14-qPCR analysis (Data file 14). The SCND-positive rate for  $P14^{ARF}$  was similar to that for the CDKN2A CDR (31.7% vs 36.7%) (Table 2). CDKN2A SCND was found only in 19 GCs by both assays. While CDKN2A CDR SCND was significantly associated with distant metastasis of GC

1 (odd ratio=4.09, p<0.001), no association was observed between P14<sup>ARF</sup> SCND and GC metastasis. Using

merged CDKN2A SCND data (CDKN2A CDR SCND-positive and/or P14<sup>ARF</sup> SCND-positive), only a weaker

association was observed. These results suggest that individual P16-Light alone may be good enough for

detecting CDKN2A SCND in tissue samples.

#### Discussion

Somatic copy number deletion and amplication are two main kinds of SCNVs. The detection of copy number amplification of oncogenes is routinely used for precise cancer treatments. However, the detection of SCND of tumor suppressor genes is absent and its significance in clinical practices is not well studied. The reason should be the lack of feasible detection approaches. Here, we report that there are CDRs in many tumor suppressor genes, such as *CDKN2A*, *miR31HG*, *PTEN*, and *RB1*, which are commonly inactivated by SCND in various human cancers (1,2). Notably, we characterized, for the first time, the 5.1-kb true CDR from the *CDKN2A/P16*<sup>INK4A</sup> promoter to intron-2 in >90% *CDKN2A*-deleted cancers. Using the *CDKN2A* CDR as a PCR target, we further established the feasible P16-Light assay to detect *CDKN2A* SCND and amplification in tissue samples. These findings indicate that CDRs are prevalent sequences in tumor suppressor genes, and characterization of the base-resolution genomic coordinates of CDRs could enable us to setup conventient methods for SCND detection of genes.

Interstitial deletion/fusion is the main type of *CDKN2A* SCND and the breaking/fusing coordinates for *CDKN2A* SCNDs in cancer genomes are diverse, which blocks the establishment of a feasible detection assay for *CDKN2A* SCND, although many efforts have been afforded (20). In the present study, we initially found the 8~17-kd estimated *CDKN2A* CDR in both monoclonal cancer cell lines and cell-heterogenous cancer tissues with *CDKN2A* copy number deletion according to the SNP-array datasets from COSMIC and TCGA projects (1,12). Then, we further characterized the 5.1-kb true CDR at the base-resolution within the *CDKN2A* gene in cancer genomes using DNA sequencing data (19-28), and confirmed the CDR using WGS datasets in all 18 GCs containing *CDKN2A* SCND (13). Because the true *CDKN2A* CDR was observed in more than 90% of *CDKN2A*-deleted cancer samples and the P16-Light assay is highly reproducible and convenient, the quantitative P16-Light assay should be considered as a viable assay for detecting *CDKN2A* SCNVs in clinical practices. This is supported by the result that *CDKN2A* SCND by P16-Light was significantly associated with GC metastasis, and further supported by the results of our prospective study, in which *CDKN2A* SCND was closely associated with hematogenous metastasis of GCs (34). In another long-term prospective study, we also found that *CDKN2A* SCND and amplification by P16-Light were significantly associated with

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

malignant transformation and complete regression of mild or moderate esophageal squamous cell dysplasia, respectively (Fan et al. submitted for publication). The results of these studies also suggest that the sensitivity of 20% for the P16-Light assay may be good enough for routine clinical use. WGS is generally used as a kind of gold standard to study structural alterations of genomic DNAs, especially for insterstitial gene copy deletion/fusions. However, WGS is a cost assay and its accuracy depends on sequencing depth, WGS at sequencing depth 36× would be considered as the hemi-quantitative assay. In our calling CDKN2A SCND coordinate processes, it was found that 18 CDKN2A SCND coordinates were identified in 17 (10.8%) of 157 GCs, which was consistent with the frequency (11.4% =50/438) of homozygous deletion of CDKN2A in GCs in WES or WGS sequencing datasets (Data file 14) (35). The positive rate (25.6%) of CDKN2A SCND in 156 GCs with enough genomic DNA samples in the P16-Light analysis was more than twice of WGS. And the results of P16-Light analyses were significantly correlated with those of WGS. These phenomena suggest that P16-Light is a much more sensitive, convenient, and less expensive assay than WGS. P14-qPCR is a method used to detect the copy number of CDKN2A/P14<sup>ARF</sup> exon-1 (15). Although the combination of P16-Light with P14-qPCR may detect both SCNDs overlapped with the CDKN2A CDR and not overlapped with the CDKN2A CDR, the results of our comparison analysis among 139 GC patients showed that detecting CDKN2A SCND by individual P16-Light may be good enough for clinical practices because combination with P14-qPCR could not improve the performance of P16-Light. However, for other genes such as RB1 and PTEN, whether a qPCR array needs to be employed for detecting their SCNVs should be studied case by case. Generally, IHC is a popular method used to detect expression changes of protein-coding genes. For example, P16<sup>INK4A</sup> overexpression in cervical mucosa samples is currently used for rapidly HPV infection screening. We compared the status of P16<sup>INK4A</sup> expression by IHC between GCs with CDKN2A SCND (n=4) and without CDKN2A SCND (n=12) and did not find any difference in the P16 NK4A positive-staining rate between these GCs (3/4 vs. 9/12). The expression level of CDKN2A/P16<sup>INK4A</sup> is not only affected by SCNVs, but also regulated by the methylation status of CpG island, histone modifications, and high-risk HPV infection (36,37). These factors may partially account for the insistence between IHC and P16-Light. The driver function of the CDKN2A gene in cancer development is enigmatic. P16<sup>ink4a</sup> inactivation contributes less than P19<sup>arf</sup> (the murine counterpart of human P14<sup>ARF</sup>) inactivation to cancer development in

mice, while P16<sup>INK4a</sup> inactivation contributes more than P14<sup>ARF</sup> inactivation to cancer development in

humans (38,39). The exact mechanisms leading to the difference among species is still unclear. Here, we 1 reported that approximately 87% of genetic P16<sup>INK4a</sup> inactivation by CDKN2A SCND is accompanied by P14<sup>ARF</sup> 2 3 inactivation in human cancer cell lines or tissues. This may account for the species-related functional 4 difference of the CDKN2A gene. Th report supports this explanation that knocking out both p16<sup>ink4a</sup> and p19<sup>arf</sup> leads to more cancer development than individual inactivation in mice (40). This also may account 5 6 that  $P14^{ARF}$  exon- $1\beta$  deletion was not associated with GC metastasis whereas *CDKN2A* CDR deletion was 7 significantly associated with GC metastasis as described above. 8 In conclusion, we have found estimated CDRs in many tumor suppressor genes in the cancer genome. And there is a 5.1-kb CDR region within the CDKN2A gene, and most CDKN2A deletions lead to P16<sup>INK4a</sup> and 9 P14<sup>ARF</sup> inactivation in human cancers. Using the CDKN2A CDR as a target sequence, we developed a 10 11 convenient quantitative multiplex PCR assay, the P16-Light, to detect CDKN2A SCNVs in clinical practice, 12 suggesting that the strategy to detect CDKN2A SCNVs may be suitable for the establishment of SCNV 13 detection methods for other tumor suppressor genes. 14 **Abbreviations** 15 CDR, common deletion region; DHPLC, denaturing high performance liquid chromatography 16 17 GC, gastric carcinoma LOH, loss of heterozygosity 18 MSI, microsatellite instability 19 20 OMIM, the Online Mendelian Inheritance in Man; 21 SCND, somatic copy number deletion 22 SM, surgical margin 23 TCGA, The Cancer Genome Atlas 24 WGS, whole genome sequencing 25 Ethical approval and consent to participate: The Institution Review Board of Peking University Cancer 26 Hospital & Institute approved this study and was carried out in accordance with the principles outlined in 27 the Declaration of Helsinki. Informed consent was obtained from each patient prior to their inclusion in the

Consent for publication: Not applicable.

28

29

study.

- 1 Availability of supporting data: Detailed information on the base-resolution interstitial common deletion
- 2 region in the CDKN2A gene in 110 cancer samples and other data were provided in Supplementary Data
- 3 files 1-14.
- 4 Competing Insterests: DD, YT, JZ, and ZL are the creators for the pending patent "A quantitative method for
- 5 detection of human CDKN2A gene copy number using a primer set and their applications"
- 6 (PCT/CN2019/087172; WO2020228009). All of other authors have nothing to disclose.
- 7 Funding: This work was supported by the Beijing Natural Science Foundation (grant number 7181002 to DD);
- 8 Beijing Capital's Funds for Health Improvement and Research (grant number 2018-1-1021 to DD.). The
- 9 funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
- 10 manuscript.
- 11 Author contributions: DD designed the study, performed bioinformatics analyses, characterized base
- 12 resolution CDR coordinates in CDKN2A and other genes, and wrote the manuscript draft. JZ, YT, ZJL, and LKG
- developed the P16-Light assay and analyzed CDKN2A SCNVs in samples. RX and YYL provided the CDKN2A
- 14 CDR coordinates from whole genome sequencing datasets. All authors approved the final manuscript.
- 15 Acknowledgements: We thank Dr. Sanford Dawsey at NCI, NIH, Bethesda, Maryland for critical comments
- 16 for the manuscript. We also thank Miss Gina Mckeown in New York, USA for English language editing.
- 17 Authors' information: Professor Dajun Deng graduated from Peking Union Medical College in 1986 and
- 18 employed by Peking University Cancer Hospital (Beijing Institute for Cancer Research) from then on. His
- 19 current research activities are focused on genetic and epigenetic CDKN2A inactivation in cancer
- 20 development. He published approximately 150 scientific papers, including Mol Cancer, Nucl Acids Res,
- 21 Genome Biol, Proc Nat Acad Sci USA, Clin Cancer Res, and EBioMed. His ORCiD is 0000-0001-5161-5943.

### References

- 23 1. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, et al. The
- 24 landscape of somatic copy-number alteration across human cancers [eng]. Nature 2010 Feb;463
- 25 7283:899-905 as doi: 10.1038/nature08822.
- 26 2. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, et al. The cBio cancer
- 27 genomics portal: an open platform for exploring multidimensional cancer genomics data [eng].
- 28 Cancer Discov 2012 May; 25:401-4 as doi: 10.1158/2159-8290.CD-12-0095.

1 3. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates 2 sensitive and confident localization of the targets of focal somatic copy-number alteration in 3 human cancers [eng]. Genome Biol 2011;12 4:R41. Epub 2011/04/28 as doi: 10.1186/gb-2011-12-4-r41. 4 5 4. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, et al. Integrative analysis of 6 complex cancer genomics and clinical profiles using the cBioPortal [eng]. Sci Signal 2013 Apr;6 7 269:pl1. Epub 2013/04/02 as doi: 10.1126/scisignal.2004088. 8 5. Network CGAR, University AWGA, Agency BC, Hospital BaWs, Institute B, University B, University 9 CWR, et al. Integrated genomic characterization of oesophageal carcinoma [eng]. Nature 2017 01 12;541 7636:169-75. Epub 20170104 as doi: 10.1038/nature20805. 10 11 6. Cui Y, Chen H, Xi R, Cui H, Zhao Y, Xu E, Yan T, et al. Whole-genome sequencing of 508 patients 12 identifies key molecular features associated with poor prognosis in esophageal squamous cell 13 carcinoma [eng]. Cell Res 2020 10;30 10:902-13. Epub 20200512 as doi: 10.1038/s41422-020-0333-6. 14 7. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho R. Role of the INK4a locus in tumor 15 suppression and cell mortality. [eng]. Cell 1996 Apr;85 1:27-37. 16 17 8. Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, et al. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation [eng]. Cancer Discov 2018 02;8 2:216-33. Epub 18 2017/11/03 as doi: 10.1158/2159-8290.CD-17-0915. 19 20 9. Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, et al. A Cancer Cell 21 Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade [eng]. Cell 2018 11;175 4:984-97.e24 as doi: 10.1016/j.cell.2018.09.006. 22 23 10. Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, et al. Cyclin D-CDK4 kinase destabilizes 24 PD-L1 via cullin 3-SPOP to control cancer immune surveillance [eng]. Nature 2018 01;553

> Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma [eng]. Clin Cancer Res 2019 Nov;25 21:6511-23. Epub 2019/08/02 as doi: 10.1158/1078-0432.CCR-19-0475.

Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, Yin T, et al. Genetic Aberrations in the CDK4 Pathway Are

25

26


27


28

29


11.

7686:91-5. Epub 2017/11/16 as doi: 10.1038/nature25015.





Jun,100 11.784-95. Epub 2006/05/27 as doi. 10.1095/jnci/djn157.



Jan;23 2:379-85 as doi: 10.1038/sj.onc.1207074.

### Figure Legends

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Figure 1. Genomic coordinates of interstitial CDKN2A deletion/fusion in human cancer genomes. (A) Estimated coordinates of CDKN2A deep-deletion in cancer tissues according to the COSMIC data. (B) True coordinates at the base-resolution of CDKN2A deletion in cancer cell lines (n=92, blue lines) and gastric cancer (n=18, purple lines) according to sequencing data. Two top charts display the coordinates of most deletion fragments. The sample ID is labeled under each column. Two bottom charts display the amplified view of these deletion fragments, where the 17-kb and 5.1-kb common deletion regions (CDRs) are highlighted with a red dashed line rectangle. The 5.1-kb true CDR from the P16<sup>INK2a</sup> promoter to intron-2 is exactly the same region as the deleted CDKN2A fragment in the HCC193 lung cancer cell line (highlighted with a black line). Each line represents a CDKN2A deletion fragment. The locations of P16<sup>INK4a</sup> and P14<sup>ARF</sup> (grey shadow) and exon- $1\alpha/1\beta/2/3$  (black dots) are also labeled as landmarks. The position of amplicons for P16-Light and P14-qPCR are respectively illustrated with violet and green lines. The detailed deletion coordinates for each sample are listed in Data file 2 and Data file 12. Figure 2. The estimated coordinates of deep-deletion fragments overlaped with tumor suppressor genes ATM, FAT1, RB1, PTEN, and miR31HG according to the COSMIC data. Common deletion region (CDR) for each gene is highlighted with a red line rectangle. The detailed deletion coordinates for each sample are listed in Data file 3 and Data file 11. Figure 3. Detection of the copy number of CDKN2A intron-2 with quantitative gene-specific multiplex PCR (P16-Light). (A) The location of the 129-bp amplicon within the common deletion region (CDR) and its host genes. (B) The amplication efficiency of two amplicons for GAPDH and CDKN2A genes in the template titration assays using standard DNA samples from RKO cells (with two wild-type CDKN2A alleles) and A549 cells (with a homozygous CDKN2A deletion). (C) Effects of the amount of template DNA on the efficiency of PCR amplification for amplicons in CDKN2A and GAPDH genes (Left chart) and detection of the relative CDKN2A gene copy number (Right chart). (D) The linear relationship between the proportion of CDKN2A copy number deletion and ratios of RKO cells spiked with A549 cells. (E) Stability of the proportion of the CDKN2A copy number deletion by P16-Light during ten experiments over different days. The RKO cell DNA templates were spiked with 0, 10%, 20%, 25%, and 30% A549 cell DNA. Each column represents the average proportion of CDKN2A copy number deletion in triplicate. Exp. 1 - 10: the results of 10 repeated

1 experiments performed on different days. \*: compared to the 100% RKO control in chi-square test, p<0.05.

2 Figure 4. Comparisons of somatic copy number variations (SCNVs) of CDKN2A gene in gastric carcinoma

samples (GCs) from 156 patients in the P16-Light and WGS (30×) analyses. (A) The states of CDKN2A SCNVs

4 by P16-Light (relative to paired surgical margin reference) in GC groups with and without CDKN2A

deletion/fusion in the WGS analysis. (B) Comparison of the proportion of cancer cells (or sample purity; by

WGS) in GC groups with various CDKN2A SCNVs by P16-Light. The average proportion of cancer cells in each

GC group is labeled. (C) Correlation analysis between the proportion and relative copy number of the

8 CDKN2A gene in GCs.

3

5

6

7

## Table 1. Oligo sequences

Gene/STS	Assay	Oligo	Sequence (5'-3')	PCR product size	
CDKN2A	P16-Light	F-primer	caggtctgtttcctcatttg	129-bp	
	P16-Light	R-primer	ggtcagattagttgagttgtg		
	P16-Light	Probe	FAM-ctggctggaccaacctcagg-BHQ1		
	P14-qPCR	F-primer	ggaggcggcgagaacat	92-bp	
	P14-qPCR	R-primer	tgaaccacgaaaaccctcact		
	P14-qPCR	Probe	V   C-tgcgcaggttcttggtgaccctcc-TAMRA		
G APDH	P16-Light	F-primer	gctcacatattctggaggag	135-bp	
	P16-Light	R-primer	ggtcattgatggcaacaata		
	P16-Light	Probe	Cy5-tgccttcttgcctcttgtctctt-BHQ2		
	P14-qPCR	F-primer	ccactaggcgctcactgttct	97-bp	
	P14-qPCR	R-primer	gcgaactcacccgttgact		
	P14-qPCR	Probe	FAM-ctccctccgcgcagccgagc-TAMRA		

**Table 2.** Association between clinicopathological characteristics and *CDKN2A* SCND detected by P16-Light and P14-qPCR

1

2

3

			CDKN2A CDR CDKN2A P14 <sup>ARI</sup>			<b>214</b> <sup>ARF</sup>	CDKN2A CDR or P14 <sup>ARF</sup> CDKN2A CDR & P14 <sup>ARF</sup>			
			SCND-positive by P16-Light		SCND-positive by P14-qPCR		SCND-positive		SCND-positive	
			Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive
		n	cases	rate (%)	cases	rate (%)	cases	rate (%)	cases	rate (%)
Age	<60	68	23	33.8	18	26.5	33	48.5	8	11.8
	≥60	71	28	39.4	26	36.6	43	60.6	11	15.5
Sex	Male	101	40	39.6	33	32.7	58	57.4	15	14.9
	Female	38	11	28.9	11	28.9	18	47.4	4	10.5
Location	Cardiac	18	9	50.0	3	16.7	10	55.6	2	11.1
	Non-cardiac	121	42	34.7	41	33.9	66	54.5	17	14.0
Different.	Poor	99	33	33.3	30	30.3	51	51.5	12	12.1
	Well/mod.	37	16	43.2	14	37.8	23	62.2	7	18.9
pTNM	1-11	46	11	23.9°	16	34.8	23	50.0	4	8.7
stage	III	37	14	37.8	8	21.6	17	45.9	5	13.5
	IV	56	26	46.4	20	35.7	36	64.3	10	17.9
Invasion	T1-2	27	11	40.7	13	48.1	19	70.4	5	18.5
	T3	79	28	35.4	19	24.1	38	48.1	9	11.4
	T4	33	12	36.4	12	36.4	19	57.6	5	15.2
Lymph	Negative	51	16	31.4	18	35.3	27	52.9	7	13.7
metastasis	Positive	88	35	39.8	26	29.5	49	55.7	12	13.6
Distant	Negative	107	31	29.0 <sup>b</sup>	33	30.8	53	49.5 °	11	10.3 <sup>d</sup>
metastasis	Positive	32	20	62.5	11	34.4	23	71.9	8	25.0
(Total)		139	51	36.7	44	31.7	76	54.7	19	13.7

<sup>&</sup>lt;sup>a</sup> Chi-square trend test, p<0.001; <sup>b</sup> Odds ratio (OR) =4.09, 95% confidence interval (CI) (4.66-10.19), p=0.001;

<sup>&</sup>lt;sup>C</sup> OR =2.60, 95%Cl (1.03-6.74), *p* <0.026; <sup>d</sup> OR =2.91, 95%Cl (0.94-8.94), *p*=0.033

